Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 5/20 | 0.46 |
| ▸ | CNR1 | P21554 | 1/20 | 0.42 |
| ▸ | CNR2 | P34972 | 1/20 | 0.42 |
| ▸ | DRD2 | P14416 | 4/20 | 0.41 |
| ▸ | DRD3 | P35462 | 4/20 | 0.41 |
| ▸ | CCR2 | P41597 | 1/20 | 0.41 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.40 |
| ▸ | RBP4 | P02753 | 1/20 | 0.40 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.39 |
| ▸ | KDM1A | O60341 | 1/20 | 0.39 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL4228572 | 1.00 | HTR2A (0.46) | HTR2ACNR1CNR2DRD2DRD3 | |
| SCHEMBL17041285 | 0.79 | DRD2 (0.47) | HTR2ACNR1CNR2DRD2DRD3 | |
| Trifluoroacetic Acid SCHEMBL4227904 | 0.78 | ALDH1A1 (0.50) | — | |
| SCHEMBL7857614 | 0.77 | HTR2A (0.51) | HTR2ACNR1CNR2SSTR4TRPV1 | |
| SCHEMBL27125516 | 0.75 | TRPV1 (0.50) | CNR1CNR2TRPV1 | |
| SCHEMBL26962614 | 0.75 | TRPV1 (0.50) | CNR1CNR2TRPV1 | |
| SCHEMBL7502344 | 0.74 | HTR2A (0.46) | HTR2ACNR1CNR2 | |
| SCHEMBL11666222 | 0.74 | HTR2A (0.45) | HTR2AKDM1A | |
| SCHEMBL4334884 | 0.73 | HTR2A (0.46) | HTR2ACNR1CNR2DRD2DRD3 | |
| SCHEMBL6413848 | 0.73 | HTR2A (0.51) | HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2096104-A1 | Organic diamines as mGluR7 modulators | Novartis AG (CH) | 2009-09-02 | — | — | EP | disclosed |
| US-20080242698-A1 | Organic Compounds | NOVARTIS AG (CH) | 2008-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080242698-A1 | Organic Compounds | AOC1, OTC, ODC1 | HTR2A 3353/4885CNR1 3533/4885CNR2 2744/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.